Compare Aptiv PLC (APTV) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs GSK plc — how do they compare? Aptiv PLC trades at $49.46 (market cap $10.30B), while GSK plc trades at $50.32 (market cap $102.60B). The key difference: GSK plc is far larger — about 10× Aptiv PLC's market cap, and GSK plc pays a 3.57% dividend while Aptiv PLC pays none. Which is the better fit depends on your goals.
| APTV | GSK | |
|---|---|---|
Market Cap | $10.30B | $102.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $61.18 |
52-Week Low | $46.30 | $38.22 |
Enterprise Value | $15.23B | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $49.81, up 0.52% on the day, but remains under pressure following a lowered 2026 outlook despite recent earnings beats. Technical indicators are bearish, with the stock near support at $49. Fundamentally, revenue grew to $20.40B in 2025, but net income margin compressed to 1.07%, reflecting margin pressure. The company faces headwinds from China demand weakness and program delays, as highlighted in recent news.
The investment case balances a low valuation (P/E 22.45, P/S 0.52) and strong analyst buy ratings (63.64% buy) against near-term execution risks and cash flow volatility. Upside to the $70.09 consensus target exists if operational improvements materialize, but investors must weigh guidance cuts and competitive threats in the auto sector.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
